Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Imugene ( (AU:IMU) ) just unveiled an announcement.
Imugene Limited has requested a trading halt on its securities pending an announcement regarding a proposed capital raising. This move indicates a strategic financial decision that could impact the company’s operations and market positioning, with potential implications for investors and stakeholders.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited operates in the biotechnology industry, focusing on the development of novel therapies that harness the immune system to treat cancer. The company is engaged in creating innovative immunotherapies that aim to improve the survival and quality of life for cancer patients.
YTD Price Performance: -66.22%
Average Trading Volume: 552,721
Technical Sentiment Signal: Sell
Current Market Cap: A$93.35M
See more insights into IMU stock on TipRanks’ Stock Analysis page.